$121.40
8.51% yesterday
Nasdaq, Aug 12, 10:04 pm CET

Repligen Corporation Stock price

$121.40
+0.07 0.06% 1M
-24.32 16.69% 6M
-22.54 15.66% YTD
-42.18 25.79% 1Y
-129.95 51.70% 3Y
-21.53 15.06% 5Y
+84.37 227.84% 10Y
+118.10 3,578.79% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+9.52 8.51%

Key metrics

Basic
Market capitalization
$6.3b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | 65.3
P/S
9.3 | 8.7
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
69.7%
Return on Equity
-1.3%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$674.0m | $724.2m
EBITDA
- | $144.2m
EBIT
$-23.6m | $98.9m
Net Income
$-13.8m | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
-11.4% | 14.1%
EBITDA
- | 46.2%
EBIT
-231.2% | 720.4%
Net Income
-462.0% | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
50.7%
EBITDA
- | 19.9%
EBIT
-3.5%
Net
-2.1% | -
Free Cash Flow
-
More
EPS
$-0.3
FCF per Share
-
Short interest
8.2%
Employees
2k
Rev per Employee
$360.0k
Show more

Is Repligen Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Repligen Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Repligen Corporation forecast:

22x Buy
79%
6x Hold
21%

Analyst Opinions

28 Analysts have issued a Repligen Corporation forecast:

Buy
79%
Hold
21%

Financial data from Repligen Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
674 674
11% 11%
100%
- Direct Costs 332 332
20% 20%
49%
342 342
1% 1%
51%
- Selling and Administrative Expenses 276 276
8% 8%
41%
- Research and Development Expense 47 47
11% 11%
7%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -24 -24
231% 231%
-4%
Net Profit -14 -14
462% 462%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Repligen Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Repligen Corporation Stock News

Neutral
GlobeNewsWire
13 days ago
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign's machine learning and modeling workflow into Repligen filtration systems. As part of the partnership, Repligen will invest i...
Neutral
Seeking Alpha
14 days ago
Repligen Corporation (NASDAQ:RGEN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jacob Johnson - Corporate Participant Jason K. Garland - CFO & Chief Compliance Officer Olivier Loeillot - President, CEO & Director Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Douglas Anthony Schenkel - Wolfe Rese...
Neutral
GlobeNewsWire
15 days ago
WALTHAM, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2025, covering the three- and six- month periods ended June 30, 2025. Provided in this press release are financial performance highlights, updates to our guidance for the full year...
More Repligen Corporation News

Company Profile

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Head office United States
CEO Olivier Loeillot
Employees 1,778
Founded 1981
Website www.repligen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today